About
Akari Therapeutics is an oncology biotech company developing novel antibody drug conjugates (ADCs) with its first payload, PH1, a spliceosome modulator that disrupts RNA splicing in cancer cells. Unlike traditional ADC payloads, PH1 induces cancer cell death while activating immune responses, showing robust and durable activity in preclinical models.
Tampa